Lixumistat

Overview

Lixumistat (IM156 free base) is a potent and orally active AMPK activator and OXPHOS inhibitor. Lixumistat strongly activates AMPK , while it lacks the systemic metabolic regulatory effects of classic metformin, such as hypoglycemic and weight-lowering activities. Lixumistat exhibits significant therapeutic effects on cognitive decline associated with brain aging and pulmonary fibrosis.

Application

Products | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Pulmonary Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Neurological Disease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Mitochondrial Metabolism | Products > Signaling Pathways > AMPK

Product Information

• Catalog No.: HY-136093B
• CAS No.: 1422365-93-2
• Molecular Formula: C13H16F3N5O
• Molecular Weight: 315.29
• Purity: 99.33%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (7.93 mM); Clear solution
• Availability: In-stock

Source

Original product source